Leteprinim potassium

Drug Profile

Leteprinim potassium

Alternative Names: AIT 082; Neotrofin; SPI-205

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Spectrum Pharmaceuticals
  • Class Aminobenzoic acids; Hypoxanthines; Neuroprotectants; Small molecules
  • Mechanism of Action Nerve growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Peripheral nervous system diseases
  • Discontinued Alzheimer's disease; Parkinson's disease; Spinal cord injuries

Most Recent Events

  • 21 Apr 2011 Preclinical development is ongoing
  • 23 Jun 2008 Preclinical development is ongoing
  • 11 Dec 2006 Preclinical trials in Neurological disorders in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top